You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Evaluating Oral Treatment Options for the Initial Management of Osteoarthritis

  • Authors: Philip Conaghan, MD, PhD; David A. Walsh, MD, PhD
  • CME / ABIM MOC / CE Released: 8/7/2018
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/7/2019, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, orthopedists and orthopedic surgeons, rheumatologists, nurses, and pharmacists.

The goal of this activity is to examine evidence-based clinical data regarding the use of paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain in patients with osteoarthritis (OA), as well as determine which patients would benefit from such treatments.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data relating to the use of acetaminophen vs NSAIDs for the treatment of OA
  • Have greater competence related to
    • Selecting individualized treatment using acetaminophen or NSAIDs for the management of OA


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Philip Conaghan, MBBS, PhD, FRACP, FRCP

    Professor
    University of Leeds
    Leeds, United Kingdom

    Disclosures

    Disclosure: Philip Conaghan, MBBS, PhD, FRACP, FRCP has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Bristol-Myers Squibb Company; Flexion; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Pfizer Inc.

    Dr Conaghan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Conaghan does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

  • David A Walsh, MD, PhD

    Professor
    University of Nottingham
    Director
    Arthritis Research UK Pain Center
    Nottingham, United Kingdom

    Disclosures

    Disclosure: David A. Walsh, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: Pfizer Inc.

    Dr Walsh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Walsh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Karen Badal, MD, MPH

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Karen Badal, MD, MPH, has disclosed has disclosed the following relevant financial relationships: Owns stock, stock options, or bonds from: Kallyope, Inc.

  • Heather Lewin, MAT

    Associate Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Heather Lewin, MAT, has disclosed has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Evaluating Oral Treatment Options for the Initial Management of Osteoarthritis

Authors: Philip Conaghan, MD, PhD; David A. Walsh, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 8/7/2018

Valid for credit through: 8/7/2019, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to examine evidence-based clinical data regarding the use of paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain in patients with osteoarthritis (OA), as well as determine which patients would benefit from such treatments.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print